CL2013003016A1 - Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco. - Google Patents

Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco.

Info

Publication number
CL2013003016A1
CL2013003016A1 CL2013003016A CL2013003016A CL2013003016A1 CL 2013003016 A1 CL2013003016 A1 CL 2013003016A1 CL 2013003016 A CL2013003016 A CL 2013003016A CL 2013003016 A CL2013003016 A CL 2013003016A CL 2013003016 A1 CL2013003016 A1 CL 2013003016A1
Authority
CL
Chile
Prior art keywords
bromfenac
treatment
difluprednate
prednisolone
prophylaxis
Prior art date
Application number
CL2013003016A
Other languages
English (en)
Spanish (es)
Inventor
Jason Stein
Michael Weiser
Joseph Capriotti
C Michael Samson
Bo Liang
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47139697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of CL2013003016A1 publication Critical patent/CL2013003016A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013003016A 2011-05-12 2013-10-17 Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco. CL2013003016A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161485475P 2011-05-12 2011-05-12

Publications (1)

Publication Number Publication Date
CL2013003016A1 true CL2013003016A1 (es) 2014-05-02

Family

ID=47139697

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003016A CL2013003016A1 (es) 2011-05-12 2013-10-17 Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco.

Country Status (16)

Country Link
US (1) US20150038473A1 (enExample)
EP (1) EP2707006B1 (enExample)
JP (2) JP6072009B2 (enExample)
KR (1) KR101967938B1 (enExample)
CN (1) CN103957922A (enExample)
AR (1) AR086399A1 (enExample)
AU (3) AU2012253335B2 (enExample)
BR (1) BR112013028735A2 (enExample)
CA (1) CA2835343A1 (enExample)
CL (1) CL2013003016A1 (enExample)
CO (1) CO6821949A2 (enExample)
EC (1) ECSP13013069A (enExample)
MX (1) MX360666B (enExample)
PE (1) PE20141070A1 (enExample)
TW (2) TWI717552B (enExample)
WO (1) WO2012155062A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2665195B2 (ja) 1995-05-19 1997-10-22 日本電気移動通信株式会社 Ｍｃａシステムにおける移動局の個別番号表示方法
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102154880B1 (ko) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
KR20150119303A (ko) 2013-02-15 2015-10-23 센주 세이야꾸 가부시키가이샤 항균성 금속을 함유하는 디플루프레드네이트 유액 조성물
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
LT3416654T (lt) 2016-02-18 2022-01-10 Invirsa, Inc. 5’-adenozindifosfato ribozės (adpr) medicininis panaudojimas
EP3442519A4 (en) 2016-04-14 2019-12-04 Azura Opthalmics Ltd. SELDISULFID COMPOSITIONS FOR USE IN THE TREATMENT OF THE MEIBOM DRESSING DYSFUNCTION
CA3023259A1 (en) * 2016-05-05 2017-11-09 Veloce Biopharma, Llc Compositions and methods for treatment of inflammation or infection of the eye
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR101935250B1 (ko) * 2017-07-04 2019-01-04 김대황 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물
ES2949441T3 (es) 2018-03-27 2023-09-28 Invirsa Inc Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR)
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
CN113797164B (zh) * 2020-06-17 2023-07-14 成都瑞沐生物医药科技有限公司 一种眼用制剂的载体或辅料及其制备方法和应用
CN112305115B (zh) * 2020-10-29 2022-08-23 诺峰药业(成都)有限公司 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法
KR20220062790A (ko) 2020-11-09 2022-05-17 정춘영 포비돈 아이오딘계 소독액
KR102489633B1 (ko) * 2021-01-21 2023-01-17 주식회사태준제약 점안 조성물
JP2024507326A (ja) * 2021-01-22 2024-02-19 チョンドゥー ルイムー バイオファーマスーティカルズ カンパニー リミテッド 点眼投与により乾燥型黄斑変性症および網膜光障害を予防・治療するための眼科用製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
NZ625086A (en) * 2008-06-12 2015-11-27 Foresight Biotherapeutics Inc Povidone iodine, a novel alternative preservative for ophthalmic compositions
JP2013514373A (ja) * 2009-12-15 2013-04-25 フォーサイト・バイオセラピューティクス・インコーポレーテッド 非刺激性の眼科用ポビドンヨード組成物
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物

Also Published As

Publication number Publication date
AR086399A1 (es) 2013-12-11
AU2016222491A1 (en) 2016-09-22
EP2707006B1 (en) 2019-07-03
WO2012155062A1 (en) 2012-11-15
CN103957922A (zh) 2014-07-30
AU2018203492A1 (en) 2018-06-07
CA2835343A1 (en) 2012-11-15
AU2012253335B2 (en) 2016-08-04
MX360666B (es) 2018-11-13
PE20141070A1 (es) 2014-09-14
JP6072009B2 (ja) 2017-02-01
JP2014516954A (ja) 2014-07-17
JP6359619B2 (ja) 2018-07-18
TWI717552B (zh) 2021-02-01
ECSP13013069A (es) 2015-03-31
AU2012253335A1 (en) 2013-05-02
TWI632914B (zh) 2018-08-21
TW201811340A (zh) 2018-04-01
TW201311256A (zh) 2013-03-16
EP2707006A1 (en) 2014-03-19
CO6821949A2 (es) 2013-12-31
KR101967938B1 (ko) 2019-04-10
MX2013012971A (es) 2013-12-12
BR112013028735A2 (pt) 2017-12-05
US20150038473A1 (en) 2015-02-05
KR20140045375A (ko) 2014-04-16
JP2017095474A (ja) 2017-06-01
EP2707006A4 (en) 2014-09-24

Similar Documents

Publication Publication Date Title
CL2013003016A1 (es) Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco.
MY171920A (en) Prevention and treatment of ocular conditions
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
MX369385B (es) Productos para cicatrizar heridas tisulares.
BR112014008759A2 (pt) tratamento de doença ocular
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2012009171A3 (en) Compositions and methods of treatment of corneal endothelium disorders
MX337594B (es) Formulaciones de quinonas para tratamiento de padecimientos oftalmicos.
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
CL2014000592A1 (es) Composicion oftalmica de administracion topica que comprende povidona-yodo, esteroide, anestesico, reforzador de la penetracion, preservativo antimicrobiano, cosolvente/surfactante y agente de aumento de la viscosidad; y metodo de tratamiento y/o profilaxis de un trastorno oftalmico o una infeccion por microorganismos en el ojo.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
MX345042B (es) Composiciones y métodos para tratamiento no quirúrgico de ptosis.
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
MX342183B (es) Suspension oftalmica para uso ocular.
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX374220B (es) Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados.
EP4591928A3 (en) Composition for the treatment of gastroesophageal reflux comprising hyaluronic acid
MX2016007717A (es) Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso.
MX2014011218A (es) Uso de agentes tensoactivos anfotericos para la prevencion y tratamiento de biopeliculas vaginales patogenas en infecciones vaginales.
HK1199201A1 (en) Antimicrobial peptides for treatment of infectious diseases
BR112013020195A2 (pt) composições farmacêuticas livres de citrato compreendendo anakinra
CA2909622C (en) Quinone based nitric oxide donating compounds for ophthalmic use